2025-10-20 - Analysis Report
Okay, here's a report analyzing Teladoc Health Inc. (TDOC) based on the data you provided.

## Teladoc Health Inc. (TDOC) Analysis

Teladoc Health Inc. is a telehealth company that provides virtual healthcare services.

### 1. Performance vs. S&P 500 (VOO)

*   **TDOC Cumulative Return:** -58.96%
*   **VOO Cumulative Return:** 98.09%
*   **Absolute Divergence:** -157.05%

**Divergence Analysis:**

The cumulative return of TDOC significantly underperforms the S&P 500 (VOO) by a wide margin (-157.05%).

*   **Divergence Range:** Max: 312.6, Min: -162.5
*   **Current Divergence:** -157.1
*   **Relative Divergence:** 1.1

The relative divergence of 1.1 indicates that the current divergence is near the lower end of its historical range, suggesting significant underperformance relative to the S&P 500.

**Alpha, Beta Analysis:**

| Year       | CAGR    | MDD   | Alpha   | Beta  | Cap(B) |
| :----------- | :------ | :------ | :------ | :---- | :----- |
| 2015-2017  | 77.0%   | 70.4% | 51.0%  | -0.1  | 6.2   |
| 2016-2018  | 101.0%  | 69.4% | 86.0%  | -0.1  | 8.8   |
| 2017-2019  | 141.0%  | 73.8% | 118.0% | 0.3   | 14.8  |
| 2018-2020  | 105.0%  | 80.9% | 81.0%  | 0.3   | 35.3  |
| 2019-2021  | -78.0%  | 80.9% | -125.0% | 0.3   | 16.2  |
| 2020-2022  | -252.0% | 85.9% | -251.0% | -0.9  | 4.2   |
| 2021-2023  | -315.0% | 85.9% | -316.0% | -1.8  | 3.8   |
| 2022-2024  | -93.0%  | 85.9% | -113.0% | -1.9  | 1.6   |
| 2023-2025  | -30.0%  | 81.6% | -91.0%  | -0.8  | 1.5   |

**Analysis:**

*   **CAGR:**  The compounded annual growth rate was extremely high until 2020-2022, but has become negative in recent years, indicating significant value destruction.
*   **MDD:**  Maximum Drawdown remains high, indicating a lot of volatility and potential for substantial losses.
*   **Alpha:** The alpha values are consistently negative in recent years, meaning TDOC has underperformed its benchmark after accounting for risk.
*   **Beta:** Beta values have become negative, meaning the stock moves in the opposite direction of the market.
*   **Cap(B):** Market cap has sharply declined.

### 2. Recent Price Action

*   **Current Price:** 8.53
*   **Previous Close:** 9.02
*   **Change:** -5.43%
*   **5-Day Moving Average:** 8.734
*   **20-Day Moving Average:** 8.389
*   **60-Day Moving Average:** 7.8147

**Analysis:**

The current price is below the 5-day moving average but above the 20-day and 60-day moving averages, indicating a potential short-term downtrend but a longer-term uptrend. The significant price drop (-5.43%) from the previous close suggests negative momentum and warrants caution.

### 3. Indicators

*   **Market Risk Indicator (MRI):** 0.5 (Low Investment)
*   **RSI:** 56.40
*   **PPO:** 0.26
*   **Hybrid Signal:** cash_0%_Buy 100% of cash
*   **Recent (20-day) Relative Divergence Change:** -0.2 (Negative)
*   **Expected Return:** -8697.7%

**Analysis:**

*   **MRI:** The Market Risk Indicator suggests a "Low Investment" recommendation, indicating caution.
*   **RSI:** An RSI of 56.40 is neutral, not indicating overbought or oversold conditions.
*   **PPO:** The PPO is slightly positive, suggesting a potential upward trend, but it's minimal.
*   **Hybrid Signal:** The hybrid signal suggests a full investment of cash, but this needs to be taken with a grain of salt given the other concerning indicators.
*   **Relative Divergence Change:** The negative change in relative divergence indicates short-term underperformance compared to the benchmark.
*   **Expected Return:** The extremely negative expected return (-8697.7%) raises serious concerns about the long-term investment viability of the stock.

### 4. Recent News & Significant Events

*   **Negative Sentiment:**  Multiple articles highlight Teladoc's underperformance compared to the market (e.g., "Teladoc (TDOC) Stock Sinks As Market Gains").
*   **Comparison to Competitors:**  Articles compare Teladoc to other companies in the telehealth space (e.g., "Better Beaten-Down Stock: Iovance Biotherapeutics vs. Teladoc Health").
*   **Industry News:**  Some articles focus on the broader medical sector and telehealth trends, mentioning Teladoc in passing.

The news sentiment appears largely negative, focusing on Teladoc's struggles relative to the market and competitors.

**4-2) Analyst Opinions**

*   **Consensus:** Hold
*   **Mean Rating:** 2.64 (~Hold)
*   **Target Price:** 9.18 (Average)

Analysts have a consensus rating of "Hold" with an average target price of $9.18.  This suggests limited upside potential from the current price. The lack of recent rating changes indicates no strong shifts in analyst sentiment.

### 5. Recent Earnings Analysis

| 날짜       | EPS    | 매출      |
| :--------- | :------- | :-------- |
| 2025-07-30 | -0.19  | 0.63 B$   |
| 2025-05-01 | -0.53  | 0.63 B$   |
| 2024-10-31 | -0.19  | 0.64 B$   |
| 2024-08-01 | -4.92  | 0.64 B$   |
| 2025-07-30 | -4.92  | 0.64 B$   |

**Analysis:**

*   **EPS:**  Earnings per share have been consistently negative. Notably, there appear to be duplicate dates in this table which is concerning.
*   **Revenue:** Revenue has been relatively stable around $0.63-0.64 Billion.

The earnings data shows consistent losses despite stable revenue, indicating profitability challenges.

### 6. Financial Information

| Quarter    | Revenue   | Profit Margin |
| :--------- | :-------- | :-------------- |
| 2025-06-30 | $0.63B    | 69.85%          |
| 2025-03-31 | $0.63B    | 68.73%          |
| 2024-12-31 | $0.64B    | 70.50%          |
| 2024-09-30 | $0.64B    | 71.94%          |
| 2024-06-30 | $0.64B    | 70.73%          |

| Quarter    | Equity   | ROE       |
| :--------- | :------- | :-------- |
| 2025-06-30 | $1.42B   | -2.30%    |
| 2025-03-31 | $1.43B   | -6.52%    |
| 2024-12-31 | $1.49B   | -3.25%    |
| 2024-09-30 | $1.51B   | -2.21%    |
| 2024-06-30 | $1.50B   | -55.77%   |

**Analysis:**

*   **Revenue:** Revenue has remained relatively stable across the last five quarters.
*   **Profit Margin:** Profit margins are consistently high, around 70%, which is positive. However, this doesn't translate to overall profitability due to high operating costs or other expenses.
*   **Equity:** Equity has been declining slightly.
*   **ROE:** Return on Equity is consistently negative, reflecting the company's inability to generate profits from shareholder equity.  The -55.77% in 2024-06-30 is a significant outlier and cause for concern.

### 7. Overall Assessment

Teladoc Health Inc. (TDOC) is facing significant challenges.  While revenue remains relatively stable and profit margins are high, the company is consistently losing money, resulting in negative EPS and ROE. The stock has significantly underperformed the S&P 500, and analyst sentiment is neutral. The extremely negative expected return and declining equity are major red flags. The negative news sentiment and comparison to competitors further highlight the company's struggles.

**Recommendation:**

Based on the provided data, a **sell** or **avoid** recommendation is warranted. While the hybrid signal is showing "Buy", it should be reviewed against all other indicators in the context of significant risks.
